Healthcare Business

unlike

Why Key Analyst Sees More Headwinds for Gilead Sciences

The recent performance from Gilead Sciences Inc. (NASDAQ: GILD) has analysts and investors concerned about the future. Currently the stock trades at less than eight times its forward earnings for 2016, ...
Read Full Story »
clinical trials

Why Seres Therapeutics Is Crushing Shareholders

Shares of Seres Therapeutics Inc. (NASDAQ: MCRB) took an absolute dive early in Friday’s session. The company had a market cap of nearly $1.5 billion on Thursday, but this was reduced to ...
Read Full Story »
Female patient on gurney

How AbbVie Won Big on Earnings

AbbVie Inc. (NYSE: ABBV) released its second-quarter earnings report before the markets opened on Friday. The company said that it had $1.26 in earnings per share (EPS) on $6.45 billion ...
Read Full Story »
white pills

Merck Raises EPS Outlook After Q2 Earnings

Drug giant Merck & Co. Inc. (NYSE: MRK) reported second-quarter 2016 results before markets opened Friday. The company reported quarterly adjusted diluted earnings per share (EPS) of $0.93 and revenues ...
Read Full Story »
coins

Bristol-Myers Earnings Don’t Appear to Be Enough for Investors

Bristol-Myers Squibb Co. (NYSE: BMY) released its second-quarter earnings report before the markets opened on Thursday. The company posted $0.69 in earnings per share (EPS) on $4.87 billion in revenue, ...
Read Full Story »
clinical trials

How Celgene Won With This Earnings Report

Celgene Corp. (NASDAQ: CELG) reported its second-quarter financial results before the markets opened on Thursday. This company has an outstanding partnered pipeline, which most think is low risk and has ...
Read Full Story »
Money close-up

What to Look for in Amgen Earnings

Amgen Inc. (NASDAQ: AMGN) is expected to report its second-quarter financial results after the markets close on Wednesday. In the most recent earnings report, this biotech giant beat estimates on both the ...
Read Full Story »
Prescription drugs

Short Sellers Get Selective on Major Pharma

The short interest data have been released for the July 15 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
Test tubes

JPMorgan Bullish on Biotech: 3 Top Picks to Buy Now

We have noted recently that large pharmaceuticals and biotech have been hammered, and now may be offering outstanding total return potential. While the larger pharmaceutical stocks have done better recently, the ...
Read Full Story »
biotech word cloud

Major Biotechs See Increased Short Interest Bets

The short interest data are out for the July 15 settlement date. Companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big ...
Read Full Story »
Female patient on gurney

Why Analysts Are Thinking M&A Is Back on the Table for Gilead

Gilead Sciences Inc. (NASDAQ: GILD) reported its second-quarter financial results after the markets closed on Monday. In the report we saw weakening trends in the hepatitis C vaccine (HCV) segment, ...
Read Full Story »
Medicine pills

Why Eli Lilly Earnings Are So Dynamic

Eli Lilly and Co. (NYSE: LLY) released its second-quarter earnings report before the markets opened on Tuesday. Currently this company is in the middle of a very dynamic product launch, ...
Read Full Story »
Medicine pills

Top Analyst Thinks Big Pharmaceutical Stocks Will Outperform the Rest of 2016

Ever since the Hillary Clinton high drug price tweet in September of last year, the major pharmaceuticals and biotechs have struggled, and while performance has improved over the past quarter, ...
Read Full Story »
Prescription Drugs, Pills

Why Analysts Were Not Satisfied With Gilead Earnings

Gilead Sciences Inc. (NASDAQ: GILD) reported second-quarter financial results after the markets closed on Monday. Although this is one of the world’s leading biotech companies, an earnings beat in this ...
Read Full Story »
Pills and tablets

What to Expect From Gilead Sciences Earnings

Gilead Sciences Inc. (NASDAQ: GILD) is scheduled to release its second-quarter financial results after the markets close on Monday. Within just the past month, the stock hit a 52-week low ...
Read Full Story »